Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells

被引:30
作者
Zhu, Hongcheng [1 ]
Yang, Xi [1 ]
Liu, Jia [1 ]
Zhou, Lu [2 ,3 ]
Zhang, Chi [1 ]
Xu, Liping [1 ]
Qin, Qin [1 ]
Zhan, Liangliang [1 ]
Lu, Jing [1 ]
Cheng, Hongyan [4 ]
Sun, Xinchen [1 ]
机构
[1] Nanjing Med Univ, Dept Radiat Oncol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Nanjing Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Clin Coll, Nanjing, Jiangsu, Peoples R China
[4] Nanjing Med Univ, Dept Gen Internal Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
关键词
Eukaryotic elongation factor 2 kinase; eEF2K; eEF2; Cancer; Stress; EEF2; KINASE; BREAST-CANCER; INHIBITION; PHOSPHORYLATION; EXPRESSION; INDUCTION; APOPTOSIS; AUTOPHAGY; TARGET;
D O I
10.1007/s12192-014-0545-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Eukaryotic elongation factor 2 (eEF2) is a member of the GTP-binding translation elongation factor family that is essential for protein synthesis. eEF2 kinase (eEF2K) is a structurally and functionally unique protein kinase in the calmodulin-mediated signaling pathway. eEF2K phosphorylates eEF2, thereby inhibiting eEF2 function under stressful conditions. eEF2K regulates numerous processes, such as protein synthesis, cell cycle progression, and induction of autophagy and apoptosis in cancer cells. This review will demonstrate the mechanisms underlying eEF2K activity in cancer cells under different stresses, such as nutrient deprivation, hypoxia, and DNA damage via eEF2 regulation. In vivo, in vitro, and clinical studies indicated that eEF2K may be a novel biomarker and therapeutic target for cancer.
引用
收藏
页码:217 / 220
页数:4
相关论文
共 50 条
  • [41] The role of calcium in the interaction between calmodulin and a minimal functional construct of eukaryotic elongation factor 2 kinase
    Lee, Kwangwoon
    Kumar, Eric A.
    Dalby, Kevin N.
    Ghose, Ranajeet
    PROTEIN SCIENCE, 2019, 28 (12) : 2089 - 2098
  • [42] Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase
    Johanns, M.
    Ruys, S. Pyr dit
    Houddane, A.
    Vertommen, D.
    Herinckx, G.
    Hue, L.
    Proud, C. G.
    Rider, M. H.
    CELLULAR SIGNALLING, 2017, 36 : 212 - 221
  • [43] Resveratrol Suppresses Growth of Human Ovarian Cancer Cells in Culture and in a Murine Xenograft Model: Eukaryotic Elongation Factor 1A2 as a Potential Target
    Lee, Mee-Hyun
    Choi, Bu Young
    Kundu, Joydeb Kumar
    Shin, Young Kee
    Na, Hye-Kyung
    Surh, Young-Joon
    CANCER RESEARCH, 2009, 69 (18) : 7449 - 7458
  • [44] Eukaryotic elongation factor 2 kinase regulates the development of hypertension through oxidative stress-dependent vascular inflammation
    Usui, Tatsuya
    Okada, Muneyoshi
    Hara, Yukio
    Yamawaki, Hideyuki
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2013, 305 (05): : H756 - H768
  • [45] A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors
    Xiao, Ting
    Liu, Rui
    Proud, Christopher G.
    Wang, Ming-Wei
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (06) : 557 - 563
  • [46] Resveratrol Regulates Pathologic Angiogenesis by a Eukaryotic Elongation Factor-2 Kinase Pathway
    Khan, A. A.
    Dace, D.
    Ryazanov, A. G.
    Kelly, J.
    Apte, R. S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [47] Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition
    Piserchio, Andrea
    Will, Nathan
    Giles, David H.
    Hajredini, Fatlum
    Dalby, Kevin N.
    Ghose, Ranajeet
    JOURNAL OF MOLECULAR BIOLOGY, 2019, 431 (15) : 2700 - 2717
  • [48] Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy
    Onder, Ferah Comert
    Siyah, Pinar
    Durdagi, Serdar
    Ay, Mehmet
    Ozpolat, Bulent
    RSC MEDICINAL CHEMISTRY, 2022, 13 (07): : 840 - 849
  • [49] Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy
    Wang, Huiping
    Jin, Wenke
    Li, Zixiang
    Guo, Chuanxin
    Zhang, Lan
    Fu, Leilei
    DRUG DISCOVERY TODAY, 2024, 29 (10)
  • [50] Control of CD4+ T cells to restrain inflammatory diseases via eukaryotic elongation factor 2 kinase
    Peng, Hao-Yun
    Wang, Liqing
    Das, Jugal Kishore
    Kumar, Anil
    Ballard, Darby J.
    Ren, Yijie
    Xiong, Xiaofang
    de Figueiredo, Paul
    Yang, Jin-Ming
    Song, Jianxun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)